The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Indiana's workforce is feeling pressure to return to the office, but a good portion of employees still like hybrid work. Is ...

Meridian Health Services will offer free dental exams for children ages 1 through 14 at its Meridian Dental sites on Monday, Feb. 17. The free exams will be offered from 11 a.m. to 5 p.m. for the ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

It is the largest study ever of the drug category—which includes Novo Nordisk’s GLP-1 treatments Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists Mounjaro and Zepbound.

Eli Lilly's Q4 FY24 guidance adjustment ... investment in Ireland and the $4.5 billion investment in the Lilly Medicine Foundry in Indiana, it evidences the strong demand for its products.

The company is headquartered in Indianapolis, Indiana. Read More on LLY: Eli Lilly NewsMORE Related Stocks Indices Commodities ...

In this article, we are going to take a look at where Eli Lilly And Co. (NYSE:LLY) stands against other stocks that could split in the near future. Stock splits don’t change how much a company ...